# Biomerica Inc: financial statements, quarterly

BMRA · Nasdaq · CIK 73290 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/bmra.md) · [Financials](/companies/bmra/financials.md) · [Filings](/companies/bmra/filings.md) · [Insiders](/companies/bmra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bmra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,567](/filings/0001493152-25-002209.md) | [1,017](/filings/0001641172-25-004571.md) | [1,116 d](/filings/0001641172-25-026041.md) | [1,807](/filings/0001493152-25-018043.md) | [1,636](/filings/0001493152-26-002286.md) | [1,119](/filings/0001493152-26-016388.md) | [749 d](/filings/0001493152-26-040851.md) | [1,380](/filings/0001493152-26-047271.md) | [1,210](/filings/0001493152-26-002286.md) | [987](/filings/0001493152-26-016388.md) | [875 d](/filings/0001493152-26-040851.md) | [1,265](/filings/0001493152-26-047271.md) |
| Cost of revenue | $k | [1,242](/filings/0001493152-25-002209.md) | [1,166](/filings/0001641172-25-004571.md) | [1,096 d](/filings/0001641172-25-026041.md) | [1,518](/filings/0001493152-25-018043.md) | [1,199](/filings/0001493152-26-002286.md) | [1,100](/filings/0001493152-26-016388.md) | [993 d](/filings/0001493152-26-040851.md) | [956](/filings/0001493152-26-047271.md) | [1,159](/filings/0001493152-26-002286.md) | [1,031](/filings/0001493152-26-016388.md) | [946 d](/filings/0001493152-26-040851.md) | [1,162](/filings/0001493152-26-047271.md) |
| Gross profit | $k | [325](/filings/0001493152-25-002209.md) | [(149)](/filings/0001641172-25-004571.md) | [20.0 d](/filings/0001641172-25-026041.md) | [289](/filings/0001493152-25-018043.md) | [437](/filings/0001493152-26-002286.md) | [19.0](/filings/0001493152-26-016388.md) | [(244) d](/filings/0001493152-26-040851.md) | [424](/filings/0001493152-26-047271.md) | [51.0](/filings/0001493152-26-002286.md) | [(44.0)](/filings/0001493152-26-016388.md) | [(71.0) d](/filings/0001493152-26-040851.md) | [103](/filings/0001493152-26-047271.md) |
| Research and development | $k | [412](/filings/0001493152-25-002209.md) | [343](/filings/0001641172-25-004571.md) | [265 d](/filings/0001641172-25-026041.md) | [297](/filings/0001493152-25-018043.md) | [257](/filings/0001493152-26-002286.md) | [217](/filings/0001493152-26-016388.md) | [252 d](/filings/0001493152-26-040851.md) | [212](/filings/0001493152-26-047271.md) | [193](/filings/0001493152-26-002286.md) | [178](/filings/0001493152-26-016388.md) | [205 d](/filings/0001493152-26-040851.md) | [206](/filings/0001493152-26-047271.md) |
| Selling, general and administrative | $k | [1,521](/filings/0001493152-25-002209.md) | [1,508](/filings/0001641172-25-004571.md) | [1,283 d](/filings/0001641172-25-026041.md) | [1,360](/filings/0001493152-25-018043.md) | [1,173](/filings/0001493152-26-002286.md) | [1,012](/filings/0001493152-26-016388.md) | [1,068 d](/filings/0001493152-26-040851.md) | [1,330](/filings/0001493152-26-047271.md) | [1,231](/filings/0001493152-26-002286.md) | [1,076](/filings/0001493152-26-016388.md) | [1,257 d](/filings/0001493152-26-040851.md) | [1,124](/filings/0001493152-26-047271.md) |
| Operating income | $k | [(1,608)](/filings/0001493152-25-002209.md) | [(2,000)](/filings/0001641172-25-004571.md) | [(1,528) d](/filings/0001641172-25-026041.md) | [(1,368)](/filings/0001493152-25-018043.md) | [(993)](/filings/0001493152-26-002286.md) | [(1,210)](/filings/0001493152-26-016388.md) | [(1,564) d](/filings/0001493152-26-040851.md) | [(1,118)](/filings/0001493152-26-047271.md) | [(1,373)](/filings/0001493152-26-002286.md) | [(1,298)](/filings/0001493152-26-016388.md) | [(1,533) d](/filings/0001493152-26-040851.md) | [(1,227)](/filings/0001493152-26-047271.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [8.0](/filings/0001493152-25-002209.md) | [4.0](/filings/0001641172-25-004571.md) | [7.0 d](/filings/0001641172-25-026041.md) | [4.0](/filings/0001493152-25-018043.md) | [(3.0)](/filings/0001493152-26-002286.md) | [(4.0)](/filings/0001493152-26-016388.md) | [5.0 d](/filings/0001493152-26-040851.md) | [3.0](/filings/0001493152-26-047271.md) | [5.0](/filings/0001493152-26-002286.md) | [8.0](/filings/0001493152-26-016388.md) | [6.0 d](/filings/0001493152-26-040851.md) | [6.0](/filings/0001493152-26-047271.md) |
| Net income | $k | [(1,507)](/filings/0001641172-25-004571.md) | [(1,918)](/filings/0001641172-25-004571.md) | [(1,421) d](/filings/0001641172-25-026041.md) | [(1,316)](/filings/0001493152-26-016388.md) | [(950)](/filings/0001493152-26-016388.md) | [(1,163)](/filings/0001493152-26-016388.md) | [(1,544) d](/filings/0001493152-26-040851.md) | [2.0](/filings/0001493152-26-047271.md) | [(1,320)](/filings/0001493152-26-016388.md) | [(1,312)](/filings/0001493152-26-016388.md) | [(1,145) d](/filings/0001493152-26-040851.md) | [(1,232)](/filings/0001493152-26-047271.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001493152-25-002209.md) | [(0.11)](/filings/0001641172-25-004571.md) | not reported | [(0.63)](/filings/0001493152-25-018043.md) | [(0.06)](/filings/0001493152-26-002286.md) | [(0.48)](/filings/0001493152-26-016388.md) | not reported | [0.00](/filings/0001493152-26-047271.md) | [(0.45)](/filings/0001493152-26-002286.md) | [(0.44)](/filings/0001493152-26-016388.md) | not reported | [(0.37)](/filings/0001493152-26-047271.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001493152-25-002209.md) | [(0.11)](/filings/0001641172-25-004571.md) | not reported | [(0.63)](/filings/0001493152-25-018043.md) | [(0.06)](/filings/0001493152-26-002286.md) | [(0.48)](/filings/0001493152-26-016388.md) | not reported | [0.00](/filings/0001493152-26-047271.md) | [(0.45)](/filings/0001493152-26-002286.md) | [(0.44)](/filings/0001493152-26-016388.md) | not reported | [(0.37)](/filings/0001493152-26-047271.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | period not labelled (2025-05-13) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-26) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.3](/filings/0001493152-24-014474.md) | [4.2](/filings/0001641172-25-026041.md) | [2.8](/filings/0001493152-24-041156.md) | [2.4](/filings/0001493152-25-002209.md) | [3.1](/filings/0001641172-25-004571.md) | [2.4](/filings/0001493152-26-016388.md) | [2.4](/filings/0001493152-26-040851.md) | [3.1](/filings/0001493152-25-018043.md) | [2.5](/filings/0001493152-26-002286.md) | [1.3](/filings/0001493152-26-016388.md) | [0.5](/filings/0001493152-26-040851.md) | [2.7](/filings/0001493152-26-047271.md) |
| Current assets | $m | [8.8](/filings/0001493152-24-014474.md) | [7.7](/filings/0001641172-25-026041.md) | [6.4](/filings/0001493152-24-041156.md) | [5.9](/filings/0001493152-25-002209.md) | [6.2](/filings/0001641172-25-004571.md) | [4.9](/filings/0001493152-26-016388.md) | [4.9](/filings/0001493152-26-040851.md) | [5.9](/filings/0001493152-25-018043.md) | [5.2](/filings/0001493152-26-002286.md) | [4.1](/filings/0001493152-26-016388.md) | [4.0](/filings/0001493152-26-047271.md) | [5.4](/filings/0001493152-26-047271.md) |
| Total assets | $m | [10.3](/filings/0001493152-24-014474.md) | [9.3](/filings/0001641172-25-026041.md) | [7.9](/filings/0001493152-24-041156.md) | [7.3](/filings/0001493152-25-002209.md) | [7.4](/filings/0001641172-25-004571.md) | [5.9](/filings/0001493152-26-016388.md) | [5.9](/filings/0001493152-26-040851.md) | [6.9](/filings/0001493152-25-018043.md) | [6.0](/filings/0001493152-26-002286.md) | [4.9](/filings/0001493152-26-016388.md) | [6.8](/filings/0001493152-26-047271.md) | [8.1](/filings/0001493152-26-047271.md) |
| Current liabilities | $m | [2.0](/filings/0001493152-24-014474.md) | [2.2](/filings/0001641172-25-026041.md) | [2.2](/filings/0001493152-24-041156.md) | [1.9](/filings/0001493152-25-002209.md) | [1.6](/filings/0001641172-25-004571.md) | [1.7](/filings/0001493152-26-016388.md) | [1.7](/filings/0001493152-26-040851.md) | [1.7](/filings/0001493152-25-018043.md) | [1.6](/filings/0001493152-26-002286.md) | [1.6](/filings/0001493152-26-016388.md) | [2.5](/filings/0001493152-26-047271.md) | [2.8](/filings/0001493152-26-047271.md) |
| Total liabilities | $m | [2.5](/filings/0001493152-24-014474.md) | [2.7](/filings/0001641172-25-026041.md) | [2.5](/filings/0001493152-24-041156.md) | [2.2](/filings/0001493152-25-002209.md) | [1.8](/filings/0001641172-25-004571.md) | [1.8](/filings/0001493152-26-016388.md) | [1.8](/filings/0001493152-26-040851.md) | [1.7](/filings/0001493152-25-018043.md) | [1.6](/filings/0001493152-26-002286.md) | [1.6](/filings/0001493152-26-016388.md) | [4.1](/filings/0001493152-26-047271.md) | [4.4](/filings/0001493152-26-047271.md) |
| Shareholders' equity | $m | [7.8](/filings/0001641172-25-004571.md) | [6.6](/filings/0001493152-26-040851.md) | [5.3](/filings/0001493152-26-016388.md) | [5.1](/filings/0001493152-26-016388.md) | [5.5](/filings/0001493152-26-016388.md) | [4.1](/filings/0001493152-26-016388.md) | [4.1](/filings/0001493152-26-047271.md) | [5.2](/filings/0001493152-26-047271.md) | [4.4](/filings/0001493152-26-016388.md) | [3.3](/filings/0001493152-26-016388.md) | [2.6](/filings/0001493152-26-047271.md) | [3.6](/filings/0001493152-26-047271.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(842) d](/filings/0001493152-25-002209.md) | [(1,801) d](/filings/0001641172-25-004571.md) | [(1,044) d](/filings/0001641172-25-026041.md) | [(1,344)](/filings/0001493152-25-018043.md) | [(791) d](/filings/0001493152-26-002286.md) | [(1,045) d](/filings/0001493152-26-016388.md) | [(662) d](/filings/0001493152-26-040851.md) | [(268)](/filings/0001493152-26-047271.md) | [(991) d](/filings/0001493152-26-002286.md) | [(1,250) d](/filings/0001493152-26-016388.md) | [(912) d](/filings/0001493152-26-040851.md) | [(802)](/filings/0001493152-26-047271.md) |
| Capital expenditure | $k | [6.0 d](/filings/0001493152-25-002209.md) | [0.0 d](/filings/0001641172-25-004571.md) | [24.0 d](/filings/0001641172-25-026041.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.5](/filings/0001493152-24-002331.md) | [13.5](/filings/0001493152-24-014474.md) | [16.8](/filings/0001493152-24-041156.md) | [16.8](/filings/0001493152-25-002209.md) | [16.8](/filings/0001641172-25-004571.md) | [2.1](/filings/0001493152-25-018043.md) | [2.1](/filings/0001493152-26-002286.md) | [2.4](/filings/0001493152-26-016388.md) | [2.6](/filings/0001493152-26-047271.md) | [2.9](/filings/0001493152-26-002286.md) | [3.0](/filings/0001493152-26-016388.md) | [3.3](/filings/0001493152-26-047271.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,598,968 at 2026-10-15, from the cover of the [10-Q filed 2026-10-15](/filings/0001493152-26-047271.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.